{"analyses":[{"ciLowerLimit":"0.895","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.139","estimateComment":"Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Adjusted geometric mean ratio","paramValue":"1.010"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.86","value":"30.09"},{"groupId":"OG001","spread":"33.19","value":"30.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: IV rituximab 500 mg/m\\^2 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 2 : Rituximab IV 500 mg/m^2"},{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: SC rituximab 1600 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 2: Rituximab SC 1600 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Only participants who entered Part 2 of the study and had PK data available were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6","title":"Part 2: Terminal Half-Life of Rituximab at Cycle 6","type":"SECONDARY","unitOfMeasure":"days"}